Enveric Biosciences (NASDAQ:ENVB – Get Free Report) is expected to be releasing its results before the market opens on Friday, March 27th. Analysts expect Enveric Biosciences to post earnings of ($55.80) per share for the quarter.
Enveric Biosciences Stock Down 2.5%
Shares of NASDAQ:ENVB opened at $1.96 on Friday. The business’s 50 day moving average is $2.74 and its 200 day moving average is $5.57. The stock has a market cap of $2.72 million, a P/E ratio of -0.05 and a beta of 0.31. Enveric Biosciences has a 52-week low of $1.82 and a 52-week high of $21.48.
Analyst Ratings Changes
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Enveric Biosciences in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Enveric Biosciences presently has an average rating of “Sell”.
Enveric Biosciences Company Profile
Enveric Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of novel psychedelic-based therapeutics for the treatment of psychiatric and neurological disorders. The company’s research platform leverages proprietary medicinal chemistry to design, synthesize and optimize molecules derived from established psychoactive compounds, with a goal of improving safety, efficacy and tolerability compared with traditional formulations.
Enveric’s preclinical pipeline features synthetic analogs of ibogaine, psilocybin and MDMA, each engineered to enhance therapeutic outcomes in conditions such as post-traumatic stress disorder, major depressive disorder and anxiety.
Further Reading
Receive News & Ratings for Enveric Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enveric Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
